EBMT-EHA CAR-T 2019 | The patient registry for monitoring long term safety of novel therapies
Martina Schüßler-Lenz
• 15 Mar 2019
In this interview, Martina Schüßler-Lenz, MD European Medicines Agency, London, UK, talks about the patient registry to help monitor adverse events and ensure patient safety when novel therapies are introduced. Dr Schüßler-Lenz was speaking from the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).
